<DOC>
	<DOCNO>NCT00373620</DOCNO>
	<brief_summary>The purpose study determine whether post-operative concurrent chemoradiation paclitaxel effective safe treatment high risk postoperative endometrial cancer patient .</brief_summary>
	<brief_title>A Safety Efficacy CCRT With Paclitaxel Adjuvant Therapy Post-Operative Advanced Endometrial Cancer Patients</brief_title>
	<detailed_description>Postoperative radiotherapy ( RT ) use adjuvant treatment high risk endometrial cancer ( HREC ) , appear reduce incidence pelvic relapse n't seem improve survival . Paclitaxel ( P ) show vitro clinical activity endometrial cancer , also potent radiosensitizer block divide cell G2/M phase . This study evaluate efficacy safety treatment concomitant weekly chemotherapy paclitaxel RT high risk advance endometrial cancer .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients undertaken total hysterectomy , bilateral salpingoophorectomy , wash cytology , pelvic paraaortic lymph node dissection Patients must diagnosis endometrioid type adenocarcinoma stage III , IV . Patients must GOG performance 0 , 1 , 2 . Patients must expect life span 6 month . Patients peripheral neurotoxicity grade 2 CTC criterion . Patients history chemotherapy radiation treatment . patient history arrhythmia , congestive heart failure . Patients intractable infection .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>endometrial cancer</keyword>
	<keyword>high risk</keyword>
	<keyword>weekly paclitaxel</keyword>
	<keyword>Cuncurrent chemoradiation</keyword>
</DOC>